Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVE: Alzheimer's disease or dementia can impose a significant burden on family and other informal caregivers. This study investigated how the inclusion of family/informal caregiver spillover effects in a cost-utility analysis may influence the reported value of Alzheimer's disease/dementia interventions. METHODS: We used PubMed to identify Alzheimer's disease or dementia cost-utility analyses published from 1 January, 2000 to 31 March, 2018. We reviewed and abstracted information from each study using a two-reader consensus process. We investigated the frequency and methods in which family/caregiver spillover costs and health effects were incorporated into cost-utility analyses, and examined how their inclusion may influence the reported incremental cost-effectiveness ratios. RESULTS: Of 63 Alzheimer's disease/dementia cost-utility analyses meeting inclusion criteria, 44 (70%) considered at least some family/caregiver spillover costs or health effects. Thirty-two studies incorporated spillover costs only, two incorporated spillover health effects only, and ten incorporated both. The most common approach for accounting for spillover was adding informal caregiving time costs to patient costs (n = 36) and adding informal caregiver quality-adjusted life-years to patient values (n = 7). In a subset of 33 incremental cost-effectiveness ratio pairs from 19 studies, incorporating spillover outcomes made incremental cost-effectiveness ratios more favorable (n = 15; 45%) or kept the intervention cost saving (n = 13; 39%) in most cases. In fewer cases, including spillover increased incremental cost-effectiveness ratios (n = 2; 6%), kept the intervention dominated [more costs/less quality-adjusted life-years] (n = 2; 6%), or changed incremental cost-effectiveness ratio from dominated to less cost/less quality-adjusted life-years (n = 1; 3%). In 11 cases (33%), adding spillover effects into analyses resulted in a lower incremental cost-effectiveness ratio that crossed a common cost-effectiveness threshold, which could have downstream implications for programs or policies that are adopted based on cost-effectiveness analysis results. DISCUSSION: Most Alzheimer's disease/dementia cost-utility analyses incorporated spillover costs, often as caregiver time costs, but considered spillover health impacts less often. In about 85% of the analyses, including Alzheimer's disease/dementia spillover cost or health effects decreased incremental cost-effectiveness ratios or kept the intervention cost saving. The broader value of an Alzheimer's disease/dementia intervention to society may in some cases be underestimated without considering these spillover effects on family and informal caregivers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069 · cited 3×
“Cost-utility analyses are cost-effectiveness analyses that quantify health benefits in terms of quality-adjusted life-years (QALYs), which combine length of life and quality of life into a single metric [18].”
Self-citationCost-Effectiveness in Health and Medicine
(2016) · doi:10.1093/acprof:oso/9780190492939.001.0001 · Cited by 1,552
End-of-Life Care and the Effects of Bereavement on Family Caregivers of Persons with Dementia
Schulz, R., Mendelsohn, A. B., Haley, W. E., Mahoney, D., Allen, R. S., Zhang, S., Thompson, L., & Belle, S. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmsa035373 · Cited by 543
Prevalence of stress, anxiety and depression in with Alzheimer caregivers
Ferrara, M., Langiano, E., Di Brango, T., De Vito, E., Di Cioccio, L., & Bauco, C. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-93 · Cited by 191
Crespo, M., López, J., & Zarit, S. H. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1321 · Cited by 98
Weycker, D., Taneja, C., Edelsberg, J., Haim Erder, M., Schmitt, F. A., Setyawan, J., & Oster, G. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188071 · Cited by 52
MacNeil Vroomen, J., Bosmans, J. E., Eekhout, I., Joling, K. J., van Mierlo, L. D., Meiland, F. J. M., van Hout, H. P. J., & de Rooij, S. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160908 · Cited by 48
Cited by
Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018
Kim, D. D., Silver, M. C., Kunst, N., Cohen, J. T., Ollendorf, D. A., & Neumann, P. J. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00942-2 · Cited by 277
Self-citationAnalytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy
Drummond, M. F., Neumann, P. J., Sullivan, S. D., Fricke, F.-U., Tunis, S., Dabbous, O., & Toumi, M. (2019) · Value in Health · doi:10.1016/j.jval.2019.03.012 · Cited by 92
Self-citationBuilding clinically relevant outcomes across the Alzheimer's disease spectrum
Rentz, D. M., Wessels, A. M., Annapragada, A. V., Berger, A., Edgar, C. J., Gold, M., Miller, D. S., Randolph, C., Ryan, J. M., Wunderlich, G., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12181 · Cited by 38
Duevel, J. A., Hasemann, L., Peña-Longobardo, L. M., Rodríguez-Sánchez, B., Aranda-Reneo, I., Oliva-Moreno, J., López-Bastida, J., & Greiner, W. (2020) · Health Economics Review · doi:10.1186/s13561-020-00288-7 · Cited by 34
Huo, Z., Chan, J. Y. C., Lin, J., Bat, B. K. K., Chan, T. K., Tsoi, K. K. F., & Yip, B. H. K. (2021) · Value in Health · doi:10.1016/j.jval.2021.05.011 · Cited by 20
Metadata
- Authors
- Lin, P.-J., D’Cruz, B., Leech, A. A., Neumann, P. J., Sanon Aigbogun, M., Oberdhan, D., & Lavelle, T. A.
- Venue
- PharmacoEconomics
- Published
- 2019-03-22
- Volume
- 37
- Issue
- 4
- Pages
- 597-608
- ISSN
- 1170-7690 (ISSN-L)
- 1179-2027
- OpenAlex
- W2923168235
- Cited by
- 69
- References
- 7
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions. https://app.cochat.ai/papers/10.1007/s40273-019-00788-3
- The paper
- Lin, P.-J., D’Cruz, B., Leech, A. A., Neumann, P. J., Sanon Aigbogun, M., Oberdhan, D., & Lavelle, T. A. (2019). Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions. PharmacoEconomics. https://doi.org/10.1007/s40273-019-00788-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.